Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACWX NASDAQ:FTSM NYSE:KDMN NASDAQ:LBPSW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACWXiShares MSCI ACWI ex U.S. ETF$60.90+0.1%$59.99$48.99▼$61.31$6.43B0.821.23 million shs744,717 shsFTSMFirst Trust Enhanced Short Maturity ETF$59.95+0.0%$59.91$59.69▼$60.16$6.35B0.03867,385 shs274,453 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACWXiShares MSCI ACWI ex U.S. ETF+0.51%-0.59%+1.38%+11.29%+10.20%FTSMFirst Trust Enhanced Short Maturity ETF+0.03%+0.08%+0.02%+0.02%+0.22%KDMNKadmon0.00%0.00%0.00%0.00%0.00%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACWXiShares MSCI ACWI ex U.S. ETFN/AN/AN/AN/AN/AN/AN/AN/AFTSMFirst Trust Enhanced Short Maturity ETFN/AN/AN/AN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACWXiShares MSCI ACWI ex U.S. ETF 2.64Moderate Buy$60.90N/AFTSMFirst Trust Enhanced Short Maturity ETF 0.00N/AN/AN/AKDMNKadmon 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACWXiShares MSCI ACWI ex U.S. ETFN/AN/AN/AN/AN/AN/AFTSMFirst Trust Enhanced Short Maturity ETFN/AN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACWXiShares MSCI ACWI ex U.S. ETFN/AN/A16.03∞N/AN/AN/AN/AN/AFTSMFirst Trust Enhanced Short Maturity ETFN/AN/A0.00∞N/AN/AN/AN/AN/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACWXiShares MSCI ACWI ex U.S. ETF$1.612.64%N/AN/AN/AFTSMFirst Trust Enhanced Short Maturity ETF$2.754.59%N/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ALatest KDMN, LBPSW, ACWX, and FTSM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/27/2025FTSMFirst Trust Enhanced Short Maturity ETFMonthly$0.21504.31%6/30/20256/30/20257/2/20256/13/2025ACWXiShares MSCI ACWI ex U.S. ETF$0.84686/16/20256/16/20256/20/20255/29/2025FTSMFirst Trust Enhanced Short Maturity ETFMonthly$0.22754.57%5/30/20255/30/20256/3/20254/29/2025FTSMFirst Trust Enhanced Short Maturity ETFMonthly$0.21304.27%4/30/20254/30/20255/2/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACWXiShares MSCI ACWI ex U.S. ETFN/AFTSMFirst Trust Enhanced Short Maturity ETFN/AKDMNKadmonN/ALBPSW4D pharmaN/AInsider OwnershipCompanyInsider OwnershipACWXiShares MSCI ACWI ex U.S. ETFN/AFTSMFirst Trust Enhanced Short Maturity ETFN/AKDMNKadmonN/ALBPSW4D pharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACWXiShares MSCI ACWI ex U.S. ETF147,000105.60 millionN/AOptionableFTSMFirst Trust Enhanced Short Maturity ETF147,000105.95 millionN/AOptionableKDMNKadmonN/A178.52 millionN/AOptionableLBPSW4D pharmaN/AN/AN/ANot OptionableKDMN, LBPSW, ACWX, and FTSM HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKDMN, LBPSW, ACWX, and FTSM Company DescriptionsiShares MSCI ACWI ex U.S. ETF NASDAQ:ACWX$60.90 +0.08 (+0.12%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The iShares MSCI ACWI ex U.S. ETF (ACWX) is an exchange-traded fund that is based on the MSCI AC World ex USA index. The fund tracks the performance of a market-cap-weighted index of international stocks. It captures 85% of the publicly available market, thus excluding small-caps. ACWX was launched on Mar 26, 2008 and is managed by BlackRock.First Trust Enhanced Short Maturity ETF NASDAQ:FTSM$59.94 +0.02 (+0.03%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The First Trust Enhanced Short Maturity ETF (FTSM) is an exchange-traded fund that is based on the Bloomberg U.S. Short Treasury Bond index. The fund is actively-managed to invest in a variety of fixed income securities with a target maturity of less than three years. FTSM was launched on Aug 5, 2014 and is managed by First Trust.Kadmon NYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
